Immunotherapy Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Immunotherapy Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Immunotherapy
Investigators at Brigham and Women's Hospital release new data on immunotherapy
April 11th, 2007
Investigators publish new data in the report "Abatacept in the treatment of rheumatoid arthritis." According to recent research published in the International Journal of Clinical Practice, "Over the past decade, biological immunotherapy has revolutionised the treatment of rheumatoid arthritis (RA). The most widely used of these therapies targets tumor necrosis factor-alpha (TNF-alpha)." "Approximately 20% of patients fail to respond to TNF-alpha antagonism, however, and a significant number of additional patients become refractory to anti-TNF-alpha therapy over time. Thus investigators have sought to target other pathogenic elements of RA using novel biological...
Source: Immunotherapy Weekly (2007-04-11)
|
